Analytik Jena AG


Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement. ----------------------------------------------------- Jena (ots Ad hoc-Service) - ANALYTIK JENA IS AWARDED EXCLUSIVE RIGHTS AGREEMENT BY CARL ZEISS JENA GMBH - Broadening product portfolio in the area of biotechnology - Sales plan for new business segment bioanalytical solutions for fiscal year 2001/2002 will double Analytik Jena AG which is listed on Frankfurt's Neuer Markt and Carl ZEISS Jena GmbH signed a far reaching exclusive rights agreement for the distribution of ConfoCor 2 - a system based Fluorescence Correlation Spectroscopy (FCS). Fluorescence Correlation Spectroscopy has developed into a very efficient method for analyzing molecular interactions. Owing to the unique combination of precision, speed and sensitivity with regard to free molecules, FCS has already made contributions, for instance to better understand the mechanisms of protein interaction in Alzheimer's and Creutzfeldt-Jakob diseases and complicated DNA interaction in the research field of evolutive biochemistry. As part of the agreement, Analytik Jena shall distribute ZEISS' ConfoCor 2 for industrial and scientific research and development areas in proteomic, molecular biology, neurobiology, pharmacology, biochemistry and genetics. The ConfoCor 2 is optimally designed for measuring liquid assays, for example of proteins, nucleic acids and enzymes in microcells, microtiter plates or on sample chip arrangements. In conjunction with this agreement, Analytik Jena AG will be able to significantly broaden its product competence with regard to biotechnology. As of November of this year, the marketing and distribution of this new FCS technology shall represent an additional significant business focus within the bioanalytical solutions business unit at Analytik Jena. The ZEISS cooperation signifies a considerable boost in the targeted sales growth for the immediate future. The company anticipates that this exclusive rights agreement will result in additional sales in the bioanalytical solutions business unit amounting to more than DM 7 million as of 2001/2. Thus, the sales target shall be increased from the current DM 8 million to DM 15 million. On the whole, more than DM 20 million shall be sold in the next three years as a result of this agreement. Contact: Thomas Fritsche Investor Relations Analytik Jena AG Telefon: +49-3641-201-281 Telefax: +49-3641-201-260 End ----------------------------------------------------- Internet: Original-Content von: Analytik Jena AG, übermittelt durch news aktuell

Das könnte Sie auch interessieren: